Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Group Calls for MCI Screening for Early Detection of Alzheimer’s
July 3, 2024
- New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
- Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
July 2, 2024
- MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
July 2, 2024
- PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
July 2, 2024
- PMDA Opens 1st Overseas Office in Bangkok
July 2, 2024
- Minister Wants Consensus on Future Generic Industry at Upcoming Confab
July 1, 2024
- MHLW to Revise Process to Share Info on Nitrosamine Impurities after Guidance Issued
June 28, 2024
- MHLW Project Team Proposes New Subsidies for Early R&D of Intractable Disease Drugs
June 28, 2024
- MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
June 28, 2024
- MHLW Panel OKs Different Safety Scheme for Fujimoto’s Revlimid Generic despite Concerns
June 27, 2024
- Constitutional Democratic Party Calls for Scrapping Off-Year Price Revisions
June 27, 2024
- Sakigake Tag to Be Withdrawn for Lisata’s Cell Therapy CLBS12
June 27, 2024
- Health Minister Set to Meet Generic Execs to Hear Views on Industry Revamp
June 26, 2024
- Japan's First Eylea Biosimilar Wins Nod, Potential Listing in November
June 25, 2024
- Health Ministry Changes Avigan Approval Conditions
June 25, 2024
- Japan Approves Novartis’ Fabhalta, Lilly’s Jaypirca, and Lots More
June 25, 2024
- Japan OKs Honebuto Paper, Modest Wording on Off-Year Revisions Finalized
June 24, 2024
- Japan to Obligate Single IRB in Multi-Center Clinical Trials That Use Competitive Funds
June 24, 2024
- PMDA Reviewing Safety Risks for Duvroq, Opdivo, and More
June 24, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…